- Noadjuvant chemotherapy and pathological complete remission in patients under 35 yearsPublication without faculty affiliation
- Use of Trastuzumab for Neoadjuvant Therapy of HER2+ Breast Cancer - 5-Years of Experience in a Single Clinic2018 | First Faculty of Medicine
- Current indications for systemic neoadjuvant treatment in breast cancer patients2015 | Publication without faculty affiliation
- Personalization of neo/adjuvant treatment of HER2-positive breast cancer is the key to achieve the best results2022 | First Faculty of Medicine
- Immunotherapy in the treatment of triple negative breast cancer2022 | First Faculty of Medicine
- Adjuvant breast radiotherapy after neoadjuvant systemic therapy2022 | Third Faculty of Medicine
- Current use of CAR cells in lymphoma therapy2022 | First Faculty of Medicine
- Neoadjuvant treatment of early breast cancer2019 | Publication without faculty affiliation
- Revelation in the treatment of triple-negative breast cancers2020 | First Faculty of Medicine
- Prospective non-randomized study of preoperative concurrent platinum plus 5-fluorouracil-based chemoradiotherapy with or without paclitaxel in esophageal cancer patients: long-term follow-up2010 | Publication without faculty affiliation
- Neoadjuvant chemoradiotherapy of the rectal carcinoma - The correlation between the findings on the restaging multiparametric 3T MRI scanning and the surgical findings2017 | Faculty of Medicine in Pilsen
- Treatment of HER2-positive breast cancer in 20202020 | First Faculty of Medicine